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Abstract: Endometriosis is classically defined as the presence of endometrial glands and 
stroma outside of the endometrial lining and uterine musculature. With an estimated 
frequency of 5%–10% among women of reproductive age, endometriosis is a common 
gynecologic disorder. While in itself a benign lesion, endometriosis shares several 
characteristics with invasive cancer, has been shown to undergo malignant transformation, 
and has been associated with an increased risk of epithelial ovarian carcinoma (EOC). 
Numerous epidemiologic studies have shown an increased risk of EOC among women with 
endometriosis. This is particularly true for women with endometrioid and clear cell ovarian 
carcinoma. However, the carcinogenic pathways by which endometriosis associated 
ovarian carcinoma (EAOC) develops remain poorly understood. Current molecular studies 
have sought to link endometriosis with EAOC through pathways related to oxidative stress, 
inflammation and hyperestrogenism. In addition, numerous studies have sought to identify 
an intermediary lesion between endometriosis and EAOC that may allow for the 
identification of endometriosis at greatest risk for malignant transformation or for the 
prevention of malignant transformation of this common gynecologic disorder. The 
objective of the current article is to review the current data regarding the molecular events 
associated with EAOC development from endometriosis, with a primary focus on 
malignancies of the endometrioid and clear cell histologic sub-types. 
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1. Introduction 
Endometriosis is a common gynecologic disorder. The estimated frequency among women of 
reproductive age is 5%–10% and is particularly frequent among women with pelvic pain and   
infertility [1–3]. This disorder is classically defined as the presence of endometrial glands and stroma 
outside of the endometrial lining and uterine musculature [3,4]. The exact etiology of endometriosis 
has yet to be elucidated. Mechanistic theories include: the reflux of endometrial tissue through the 
fallopian tubes at the time of menstruation, coelomic metaplasia, embryonic cell rests, and lymphatic 
and vascular dissemination [5–8]. However, it is generally accepted that endometriosis has a 
multifactorial etiology, including genetic, hormonal and immunological factors [3,6].  
Areas commonly affected by endometriosis include the surface of the ovaries and the pelvic 
peritoneum and can result in pelvic inflammation, adhesions, chronic pain and infertility [9]. While 
endometriosis is a benign lesion, it shares several characteristics with invasive cancer. Similar to 
cancer, endometriosis has the capacity to invade and spread distantly. Endometriosis can attach to, 
invade and damage affected tissues [10–12]. In addition, numerous studies indicate that women with 
endometriosis have an increased risk of developing epithelial ovarian cancer (EOC) [11,13–18]. 
Utilizing the national Swedish inpatient and cancer registry database, Brinton et al. reviewed the 
records of 20,686 women hospitalized with endometriosis between 1969 and 1983. Compared to   
age- and period-specific incidence rates from the Swedish population at that time, this cohort had an 
increased overall risk of cancer, with standardized incidence ratio (SIR) of 1.2, and 95% confidence 
intervals (CI) between 1.1 and 1.3. The risk of ovarian cancer (SIR, 95% CI; 1.9, 1.3–2.8) was also 
elevated and this was particularly pronounced among women with long-standing ovarian 
endometriosis (SIR, 95% CI; 4.2, 2.0–7.7) [14]. A follow-up to this study was conducted to determine 
whether these risk ratios were maintained in an extended study with longer follow-up. Between 1969 
and 2000, 64,492 women were evaluated. While the overall risk of cancer was not elevated, the 
elevated risk of ovarian cancer previously reported was maintained (SIR, 95% CI; 1.43, 1.19–1.71). 
Again, women with a long-standing history of endometriosis had an even greater risk of ovarian cancer 
(SIR, 95% CI; 2.23, 1.36–3.44) [15].
 
Ovarian cancers do not exist as a homogeneous group of malignancies, but as several histologic  
sub-types with unique characteristics such as frequency, disease aggressiveness, sensitivity to 
chemotherapy, and factors contributing to malignant development. Studies have shown that the risk 
associated with endometriosis varies by histologic sub-type. The greatest risk is associated with 
malignancies of endometrioid and clear cell histology [13,19,20]. Brinton et al. evaluated a   
population-based cohort of women in Denmark between 1978 and 1998 and determined that women 
with endometriosis had a predisposition to ovarian cancer. However, this association was restricted to 
endometrioid (relative risk (RR) of 2.53, 95% CI; 1.19–5.38) and clear cell (RR, 95% CI; 3.37,   
1.24–9.14) malignancies [19]. Similarly, Rossing et al. interviewed 812 women diagnosed with 
ovarian cancer. When compared to population-based controls, the risk of endometrioid/clear cell Int. J. Mol. Sci. 2013, 14 5369 
 
 
ovarian cancer for women with endometriosis was three-fold greater. In contrast, the risk associated 
with other histologic sub-types of EOC was not increased [20]. 
While epidemiologic studies have extensively evaluated the relationship between endometriosis and 
ovarian cancer, the underlying mechanism and factors involved with the malignant progression of 
endometriosis remain poorly understood. The objective of the current article is to review the current 
data regarding the genetic events and molecular changes for endometriosis-associated ovarian cancer 
(EAOC), with a primary focus on malignancies of the endometrioid and clear cell histologic sub-types.
  
2. Malignant Transformation of Endometriosis 
In 1925, Sampson was first to describe the malignant transformation of endometriosis to ovarian 
carcinoma [8].
 It was not until 70 years later that the putative progression of endometriosis to an 
ovarian malignancy was supported by molecular evidence. Jiang et al. examined DNA from 40 cases 
of endometriosis to determine if these samples harbored alterations common to ovarian malignancies. 
Specifically, alterations in TP53 and RASK, as well as allelic losses at candidate ovarian tumor 
suppressor loci on chromosome arms 6q, 9p, llq, l7p, 17q and 22q, were evaluated. Though no 
mutations were detected in TP53 or RASK, loss of heterozygosity (LOH) at one or more of the 
evaluated loci was demonstrated in 11 of 40 cases (28%) [21]. In a similar study, Sato et al. evaluated 
the tumor suppressor gene PTEN/MMAC1, located on chromosome arm 10q (10q23.3) [22,23]. LOH 
at this site occurred in 8 of 19 ovarian endometrioid carcinomas (42.1%), 6 of 22 clear cell carcinomas 
(27.3%) and 13 of 23 solitary endometriotic cysts (56.5%). In addition, somatic mutations in PTEN 
were identified in 4 of 20 ovarian endometrioid carcinomas (20.0%), 2 of 24 clear cell carcinomas 
(8.3%), and 7 of 34 solitary endometriotic cysts (20.6%) [23].  
Studies such as these support the theory that histologically benign endometriotic lesions may harbor 
genetic defects that are permissive for malignant transformation. This transformation is believed to 
progress in a step-wise fashion through an intermediary endometriotic lesion. Though the immediate 
precursor-lesion to EAOC has yet to be defined, several authors have evaluated potential targets that 
may represent the intermediary lesion. These include endometriosis contiguous with an ovarian 
malignancy and endometriosis displaying histologic features that distinguish it from completely benign 
and frankly malignant histology (i.e., “atypical endometriosis”). These histologic features, as defined 
by Czernobilsky and Morris [24] and LaGrenade and Silverberg [25], include large hyperchromatic or 
pale nuclei with moderate to marked pleomorphism; an increased nuclear-to-cytoplasmic ratio; and 
cellular crowding, stratification, or tufting. According to a study by Fukunaga et al., such atypical 
endometriosis was identified in 54% of clear cell and 42% of endometrioid ovarian carcinomas [26]. 
Separately, Ogawa et al. determined that in 37 cases of ovarian carcinomas with endometriosis, 22 
cases showed transition from typical endometriosis to atypical endometriosis, and 23 cases showed 
transition from atypical endometriosis to carcinoma [17]. Ballouk et al. found that half of the 
endometriotic cysts with severe atypia showed DNA aneuploidy, suggesting the potential of invasive 
epithelial malignancies arise in these atypical endometriotic cysts [27]. 
In the previously mentioned study by Sato et al., synchronous endometriosis was identified in five 
cases of endometrioid and seven cases of clear cell carcinoma. In the five endometrioid carcinomas 
synchronous with endometriosis, three displayed LOH events common to both the carcinoma and the Int. J. Mol. Sci. 2013, 14 5370 
 
 
endometriosis. Among the seven clear cell carcinomas synchronous with endometriosis, three 
displayed LOH events common to both the carcinoma and the endometriosis [23].
 Protein markers 
specific for ovarian malignancies have also been evaluated in the context of contiguous or atypical 
endometriosis. Hepatocyte nuclear factor-1β (HNF-1β) is a transcription factor that has been shown to 
be significantly up-regulated in ovarian clear cell carcinoma and rarely expressed in non-clear cell 
carcinoma specimens [28]. Evaluating HNF-1β, Kato et al. identified 17 clear cell tumors associated 
with endometriosis. Endometriotic epithelium was identified in 12 of these 17 cases, with a total of 
nine displaying expression of HNF-1β. Though histologically benign, the nine cases of endometriosis 
that displayed HNF-1β expression included five cases of reactive epithelium and four cases of 
“atypical endometriosis.” When a series of 40 cases of endometriosis not associated with a primary 
clear cell ovarian carcinoma were also evaluated, 16 (40%) of the cases displayed HNF-1β positivity. 
However, the authors noted that expression of HNF-1β was almost exclusively detected in the 
epithelium showing inflammatory atypia. Kato et al. thus concluded that some epithelial cells of 
ovarian endometriosis, including atypical endometriosis and endometriosis that undergoes repeated 
regenerative and inflammatory changes, have already acquired a clear cell phenotype [29]. 
 
Most recently, by transcriptomic sequencing, Wiegend et al. identified mutations of the tumor 
suppressor gene ARID1A that are common to endometrioid and clear cell ovarian carcinomas. Of 119 
ovarian clear cell carcinomas and 33 endometrioid carcinomas, ARID1A mutations were present in 55 
(46%) and 10 (30%) cases, respectively. Two sets of patient samples containing a clear cell carcinoma 
associated with contiguous atypical endometriosis were further evaluated. ARID1A mutations were 
found in the primary malignant lesion and the contiguous, atypical endometriosis. ARIDA expression 
was retained, however, in areas of endometriosis from sites distant from the primary malignant   
lesion [30]. In an immunohistochemical evaluation of ARID1A protein expression in 28 cases of 
endometriosis-associated clear cell carcinomas, Yamamoto et al. found that 17 cases (61%) were 
ARID1A negative. Within these cases, all atypical endometriosis and 86% of non-atypical 
endometriosis also lost ARID1A expression, suggesting that loss of ARID1A expression occurs as a 
very early event in the malignancy development [31]. 
3. Pathways of Carcinogenesis 
Recent whole genome or targeted sequencing studies have identified frequent mutations of ARID1A 
and  PIK3CA genes, and moderate mutations of PPP2R1A and KRAS in ovarian clear cell   
carcinomas [30,32,33], mutations of PTEN, CTNNB1 and KRAS in endometrioid cancer [34,35]. In 
combination with the results of gene expression profiling of these two tumor types [36–39], activation 
of oncogenic KRAS and PI3K survival pathways, and inactivation of tumor suppressor genes PTEN 
and  ARID1A are suggested for clear cell and endometrioid ovarian carcinomas, respectively. We 
emphasize here the significance of the following pathways in clear cell and endometrioid tumors in 
association with endometriosis. 
3.1. Oxidative Stress 
Oxidative stress has been implicated in the development of numerous human disorders. These 
include cancer, atherosclerosis, diabetes, cardiovascular disease, neurodegenerative diseases, Int. J. Mol. Sci. 2013, 14 5371 
 
 
pulmonary fibrosis, liver diseases, AIDS and aging [40]. As mentioned previously, endometriosis is 
defined as the occurrence of endometrial tissue outside of the uterus, often on the surface of the ovaries 
and the pelvic peritoneum [9]. Repetitive hemorrhage and the accumulation of heme and free iron 
within endometriotic lesions are believed to play a pivotal role in the development of ovarian 
carcinoma through the formation of reactive oxygen species (ROS) [41–43]. Yamaguchi et al. 
evaluated the contents of 21 endometriotic cysts, 4 clear cell carcinomas, and 11 non-endometriotic 
cysts to determine the concentrations of free iron and several stress-related factors (e.g., lactose 
dehydrogenase, potential antioxidant lipid peroxide, and 8-hydroxy-2'-deoxyguanosine). When 
compared to non-endometriotic cysts, the concentration of free iron in endometriotic cysts was 
significantly higher (p < 0.01). In addition, the average concentration of the evaluated stress-related 
factors was significantly greater in endometriotic cysts, when compared to non-endometriotic cysts.  
In vitro analyses showed that the contents of endometriotic cyst could produce more ROS and could 
induce gene mutations more frequently than the contents in the other cysts [42]. Similarly, Sanchez et al. 
found that markers of oxidative damage, such as strand breakage, DNA adducts and lipid peroxidation 
products could all be detected in ovarian cancer tissue [44].  
Ultimately, oxidative stress results when the production of ROS exceeds the capacity of cellular 
antioxidant defenses to remove toxic ROS [45,46]. Excess ROS can result in oxidative stress-related 
damage to proteins, lipids, DNA and the cell membrane through numerous carcinogenic DNA 
mutations or losses [47,48]. The theory that oxidative stress is implicated in the development of 
ovarian carcinoma, specifically clear cell carcinoma, is further supported by microarray   
gene-expression profiling [29,49]. Fifty-four genes have been found to be highly up-regulated in 
ovarian clear cell carcinoma. Of these 54 genes, 47 (87%) are redox-related genes, including oxidative 
and detoxification enzymes [43]. The subsequent carcinogenic pathways remain poorly understood but 
HNF-1β appears to play a key role as 22 (40.7%) of the 54 up-regulated genes are downstream targets 
of HNF-1β [49–51].  
HNF-1β is a transcription factor that targets genes encoding proteins vital to cell proliferation, 
differentiation, gluconeogenesis and glycogen synthesis [52]. The relationship between HNF-1β and 
oxidative stress has been studied in the context of viral hepatitis infection. Hepatitis C virus (HCV) 
infection induces oxidative stress during replication and/or protein expression, and chronic HCV 
infection in human liver, as well as in different experimental models, is associated with excess 
oxidative stress [53–55]. Adaptive responses to the increased oxidative burden include the activation 
of detoxification pathways via activation of HNF [55–57]. With respect to ovarian carcinoma, the 
oxidative stress related HNF-1β pathways remain largely unexplored. However, an interesting study 
conducted by Liu et al. revealed that down-regulation of HNF-1β by shRNA strategy sensitized 
ovarian cancer cells to cisplatin- or paclitaxel-induced cytotoxicity both in vitro and in vivo [58].  
3.2. Inflammation 
In 1863, Rudolf Virchow observed leukocytes in neoplastic tissues and made a connection between 
inflammation and cancer. He suggested that the “lymphoreticular infiltrate” reflected the origin of 
cancer at sites of chronic inflammation [46]. Both acute and chronic inflammations are classic features 
of endometriosis and a growing body of literature now supports the conceptualization of endometriosis Int. J. Mol. Sci. 2013, 14 5372 
 
 
as a pelvic inflammatory condition [59,60]. In women with endometriosis, the peritoneal fluid often 
contains an increased number of activated macrophages [61]. In addition, several important cytokines 
and chemokines are present in increased concentrations. These include TNF-α, IL-1β, IL-6, IL-8, 
regulated on activation normal T cell expressed and secreted (RANTES), and monocyte chemotactic 
protein-1. The latter three are chemoattractants, which facilitate the recruitment of macrophages [62–65]. 
Similar to results in endometriosis, numerous studies suggest inflammatory mediators and several 
cytokines (e.g., TNF-α, IL-1β, IL-6) promote the development, growth and progression of   
EOC [66,67]. Szlosarek et al. explored the role of TNF-α in the development of ovarian carcinoma. 
Within a cancer profile array including serous and clear cell ovarian carcinoma, the expression of 
TNF-α was increased when compared to the level of expression within normal ovarian tissue. Further, 
cultured ovarian cancer cells expressed up to 1000 times more TNF-α mRNA than cultured normal 
ovarian surface epithelium [68]. A follow-up study from the same group showed that elevated TNF 
network gene expression in the tumor microenvironment resulted in increased signaling related to 
angiogenesis, cell adhesion, cell cycle, inflammation, as well as NOTCH signaling [69]. In another 
microarray expression profiling study of endometriosis-associated endometrioid ovarian cancer, the 
expression of small inducible cytokine A2 (SICA2) and small inducible cytokine subfamily A, 
member 14 (CCL14) were the most up-regulated genes in endometriosis-associated endometrioid 
ovarian tumors when compared with benign ovaries and endometrioid cases not associated with 
endometriosis, suggesting that inflammatory cytokines are important in the etiology of endometriosis 
and associating endometrioid tumors [36]. Finally, prostaglandin E2 (PGE2) is a central mediator of the 
inflammatory response but has also been shown to regulate vital processes related to tumor growth, 
including angiogenesis, proliferation and inhibition of apoptosis [70,71]. 
3.3. Estrogen 
Numerous studies have demonstrated an association between hyperestrogenism and gynecologic 
malignancies. These include cancers of the breast, endometrium and ovary [72–74]. Specific to EAOC, 
hyperestrogenism has been associated with the malignant transformation of endometriotic cysts and 
the micro-environment provided by endometriosis facilitates the accumulation of excess estrogen 
through several mechanisms [75,76]. For example, the enzyme aromatase is normally absent in eutopic 
endometrial tissue, but present in high levels within endometriotic tissue [77]. This enzyme catalyzes 
the conversion of androstenedione and testosterone, derived from ovarian and adrenal sources, to 
estrone and estradiol (E2), respectively [78]. In endometriotic tissue, this results in the constitutive 
expression of E2 [79]. Next, endometriotic tissues lack the enzyme 17β-hydroxysteroid-dehydrogenase 
(17β-HSD) type 2, which is present in eutopic endometrial tissue and serves to convert E2 to estrone, 
which is a less potent estrogen [80]. In contrast, 17β-HSD type 1 converts estrone to the more potent 
E2 and this enzyme can be found in endometriotic tissue with the cumulative effect of increasing  
the local concentration of highly estrogenic E2 through increased production and decreased   
inactivation [78,80].  
Excess E2 can result in cellular proliferation through the stimulation of cytokine production, 
specifically IL-8 and RANTES [81]. In addition, E2 stimulates the production of PGE2. As previously 
mentioned, PGE2 promotes tumor growth, but also serves to stimulate the activity of aromatase, Int. J. Mol. Sci. 2013, 14 5373 
 
 
thereby resulting in a positive feedback loop in favor of continuous estrogen formation in 
endometriosis [77,78]. In sum, the micro-environment in endometriotic tissue is marked by 
proliferative pressure with an enhanced level of reparative activity and thus, a higher chance for DNA 
damage and mutations. 
Among EAOC, expression of estrogen receptor (ER) and progesterone receptor (PR) is 
predominantly found in the endometrioid sub-type. The clear cell sub-type typically does not express 
ER or PR [82]. The previously described events, mediated by oxidative stress and inflammation 
secondary to the repeated hemorrhage from endometriosis, result in DNA methylation that has been 
linked to decreased ER expression [83,84]. Some investigators have postulated a dualistic model for 
the development of EAOC, in which the loss of ER expression marks a pivotal point in the 
carcinogenic pathway separating the development of estrogen-dependent carcinomas (i.e., endometrioid) 
from estrogen-independent carcinomas (i.e., clear cell) [85,86]. While the separation of   
estrogen-dependent and estrogen-independent EAOC is supported on the basis of morphology and 
genomics, the details of both pathways remain areas of further investigation [85,86].  
4. Conclusions 
The association between endometriosis and EOC has been supported by years of epidemiologic 
research. Our current knowledge of this association at the molecular level remains an area of great 
interest and worthy of future studies as the carcinogenic mechanisms and pathways remain poorly 
defined. Future studies will clarify the roles of oxidative stress, inflammation and estrogen in the 
development of EAOC. At this point, we know that the micro-environment of endometriosis and 
EAOC share similar cytokines and mediators. Whether this similarity represents a link between 
endometriosis and EAOC or simply an employment of common signaling molecules to two separate 
lesions remains to be seen. Studies evaluating the possible intermediary lesion of EAOC (both 
contiguous and “atypical” endometriosis) appear promising in strengthening the link between 
endometriosis and ovarian carcinoma. These studies may also aid in identifying endometriotic lesions 
at greatest risk of malignant transformation. However, most of the specimens harboring these features 
are in formalin-fixed, paraffin-embedded (FFPE) form, which presents a challenge for successful 
molecular profiling and analysis. In conclusion, EAOC represents a poorly understood consequence of 
a common gynecologic disorder (i.e., endometriosis). A greater understanding of the pathogenesis of 
EAOC would potentially allow for preventative strategies for those women with endometriosis at 
greatest risk of developing EAOC, as well as novel treatment approaches for women already diagnosed 
with EAOC. 
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